Theralase Technologies Inc. (TLTFF)

Theralase Technologies Inc. is a clinical-stage pharmaceutical and healthcare technology company listed on OTC Markets as common stock. Based in Toronto, Canada, the company focuses on the research, development, and commercialization of light-activated photodynamic compounds and related drug formulations for cancer, bacterial, and viral applications in Canada, the United States, and other international markets. Its operations are organized into Drug Division and Device Division segments. The company also develops super-pulsed laser systems used for chronic knee pain and related nerve, muscle, and joint conditions, and it markets controller-less cool laser therapy systems, including TLC-900, TLC-300, and TLC-100, to healthcare practitioners for pain management uses. Theralase is also advancing TLD-1433 in Phase II clinical testing for Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer carcinoma in situ. In addition, it has collaborated with Canada’s National Microbiology Laboratory on research toward a Canadian-based SARS-CoV-2 vaccine.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.